Novavax, a late-stage biotechnology company developing the NVX-CoV2373 coronavirus vaccine candidate against SARS-CoV-2 has secured two manufacturing agreements for large-scale GMP (good manufacturing practice) manufacture of components of the vaccine candidate.
NVX CoV2373 is engineered from the genetic sequence of SARS CoV 2 and was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein; the vaccine contains the company’s saponin-based Matrix-M adjuvant designed to enhance the immune response and stimulate high levels of neutralizing antibodies. A Phase I clinical trial was initiated in May 2020.
